<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04176016</url>
  </required_header>
  <id_info>
    <org_study_id>OTS3050102</org_study_id>
    <nct_id>NCT04176016</nct_id>
  </id_info>
  <brief_title>Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma</brief_title>
  <official_title>Safety Study of Radiolabeled (111In or 90Y) OTSA101-DTPA, an Anti-Frizzled Homolog 10 (FZD10) Monoclonal Antibody, to Evaluate Safety and Pharmacokinetics in Patients With Relapsed or Refractory Synovial Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OncoTherapy Science, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OncoTherapy Science, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and pharmacokinetics as well as the&#xD;
      biodistribution of OTSA101-DTPA-111In and to evaluate the safety of intravenous&#xD;
      administration of OTSA101-DTPA-90Y.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) and Biodistribution of OTSA101-DTPA-111In</measure>
    <time_frame>up to 72 hours post dosing</time_frame>
    <description>Concentration of OTSA101-DTPA in plasma and the distribution of OTSA101-DTPA in the body by imaging scan will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of OTSA101-DTPA-111In</measure>
    <time_frame>up to 10 days post dosing</time_frame>
    <description>This outcome will be evaluated via overall listing of Treatment-Emergent Adverse Events and the incidence of each Treatment-Emergent Adverse Event that meets DLT criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of OTSA101-DTPA-90Y</measure>
    <time_frame>up to 6 weeks post dosing</time_frame>
    <description>This outcome will be evaluated via overall listing of Treatment-Emergent Adverse Events and the incidence of each Treatment-Emergent Adverse Event that meets DLT criteria.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Relapsed or Refractory Synovial Sarcoma</condition>
  <arm_group>
    <arm_group_label>Single Study Arm, no competitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTSA101-DTPA-111In</intervention_name>
    <description>single IV injection, 185MBq/body</description>
    <arm_group_label>Single Study Arm, no competitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTSA101-DTPA-90Y</intervention_name>
    <description>IV injection (max. 3 injections per patient), 1110MBq/body</description>
    <arm_group_label>Single Study Arm, no competitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with a documented relapsed or refractory synovial sarcoma after standard&#xD;
             chemotherapy&#xD;
&#xD;
          2. Patients â‰¥18 years of age at the time of obtaining informed consent&#xD;
&#xD;
          3. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of&#xD;
             0 or 1&#xD;
&#xD;
          4. Patients with measurable lesion&#xD;
&#xD;
          5. Patients not received any anti-malignancy agent or specified surgical intervention&#xD;
             within 28 days or specified radiotherapy within 14 days prior to study registration.&#xD;
&#xD;
          6. Patients without any clinically significant laboratory abnormality.&#xD;
&#xD;
          7. Patients with adequate heart function as measured by echocardiography or multiple&#xD;
             gated acquisition scan (MUGA).&#xD;
&#xD;
          8. Patients with adequate pulmonary function as measured by pulmonary function tests.&#xD;
&#xD;
          9. Patients who are either not of childbearing potential or who agree to use a&#xD;
             contraception method during the study and for 12 months after the last dose of study&#xD;
             drug&#xD;
&#xD;
         10. Patients must be able to understand and be willing to sign a written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with documented concurrent malignancy.&#xD;
&#xD;
          2. Patients with brain metastasis with clinical symptoms.&#xD;
&#xD;
          3. Patients with any infection requiring systemic treatment.&#xD;
&#xD;
          4. Patients with lung inflammation or pulmonary fibrosis.&#xD;
&#xD;
          5. Patients with a known history of hypersensitivities to antibody agents or serum&#xD;
             albumin agents.&#xD;
&#xD;
          6. Patients with a known history of autoimmune diseases.&#xD;
&#xD;
          7. Patients with myocardial infarction (MI) within 6 months prior to study registration.&#xD;
&#xD;
          8. Patients with uncontrolled diseases.&#xD;
&#xD;
          9. Patients with any disease requiring continuous systemic administration of steroids or&#xD;
             immunosuppressants.&#xD;
&#xD;
         10. Patients with evidence of active HBV, HCV or HIV infection.&#xD;
&#xD;
         11. Pregnant or breastfeeding female patients, or female patients with suspected&#xD;
             pregnancy.&#xD;
&#xD;
         12. Patients who are participating any other investigational treatments during the study.&#xD;
&#xD;
         13. Patients with psychiatric disorders and is considered to have difficulty to study&#xD;
             participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>OncoTherapy Science</last_name>
    <phone>+81-44-820-8251</phone>
    <email>info@oncotherapy.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Osaka International Cancer Institute</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satoshi Takenaka, M.D.</last_name>
      <phone>See Central Contact</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Institute Hospital of JFCR</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keisuke Ae, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kan Yonemori, M.D</last_name>
      <phone>See Central Contact</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Synovial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
    <mesh_term>Pentetic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

